Exploring Pharmaceutical Pellets, DC Granules and MUPS at CPHI India 2026
Explore pharmaceutical pellets, DC granules, MUPS and modified-release formulations with Rraynex Pharmaceuticals at CPHI India 2026, Stall Number 1A50.
R
Rraynex Editorial Team
4 min read
23–25 November 2026Stall Number 1A50Yashobhoomi, New Delhi
Overview
Pharmaceutical formulation development requires a clear view of material characteristics, manufacturing requirements, release profiles and quality specifications. At CPHI India 2026, formulation scientists and procurement teams can compare pharmaceutical pellets, direct-compression granules and multiple-unit pellet systems.
Rraynex Pharmaceuticals invites buyers seeking pellets and DC granules at CPHI India to Stall Number 1A50, from 23–25 November 2026 at IICC, Yashobhoomi, Dwarka, New Delhi. Start with our CPHI participation guide and identify the catalogue references you want to discuss.
Pharmaceutical pellets and specialised release technologies
Pellets provide a platform for multiparticulate drug delivery. Depending on the active ingredient and design, the release objective may be immediate, sustained, enteric or delayed. Rraynex's catalogue and corporate profile describe molecules and combination formulations across these platforms. For capsule-filling pellets, describe the intended filling process and ask which particle and handling characteristics need to be assessed.
Compare pellet, DC granule and MUPS discussion topics
Platform
What to bring to CPHI
Technical review
Coated pharmaceutical pellets
Active identity, loading basis and intended release profile
Particle characteristics, coating integrity and the relevant dissolution method.
Direct-compression granules
Target active content, tablet weight and planned press conditions
Flow, handling, compaction and finished-tablet testing.
MUPS
Pellet reference, intended tablet process and excipient assumptions
Pellet distribution and release performance after compression.
Enteric-coated pellets at CPHI India
Enteric-coated pellets are designed to resist release under specified acidic conditions and release according to the intended formulation profile. Ask about the acid stage, the change of medium and subsequent release criteria for the proposed material.
Buyers comparing sustained-release pellets at CPHI should specify the time points and test conditions of interest. Immediate-release enquiries should identify the intended dosage form and applicable dissolution requirements. Release performance needs product-specific technical data. EMA quality guidance for oral modified-release products
For combination pellets at CPHI India, state the active content and expression basis for each component, the intended release profile and whether separate populations or a blend are required. Pharmaceutical pellets catalogue
MUPS manufacturers at CPHI India
A multiple-unit pellet system incorporates multiple pellet units into a suitable final dosage form. For a MUPS tablet, blending and compression can affect pellet integrity and release. Bring your planned process, test criteria and trial quantities when discussing the material.
Direct compression uses material suited to the intended tablet process. Give the technical team the target content, uncoated tablet weight and tooling or press requirements. Ask which flow, moisture, compaction and finished-tablet results will support your trial.
The profile additionally lists Metformin HCl SR and IR granules, Gliclazide IR, Empagliflozin, Amlodipine, Telmisartan, Fexofenadine, Montelukast and Telmisartan + Hydrochlorothiazide DC granules. Confirm the proposed composition and processing suitability for each item. A granule listing alone does not establish suitability for direct compression.
Manufacturing capacity and quality review
Company-stated capacities in the Rraynex corporate profile include 145 MT/month — pharmaceutical pellets and 75 MT/month — pharmaceutical granules. The profile identifies Boisar, Tarapur MIDC for pellets, granules and MUPS. Ask which site and process apply to the material being proposed. Corporate profile
Discuss the product specification, release tests, batch traceability and the current documents available for the intended market. Use the quality documentation page and manufacturing page to prepare the review.
Explore formulation opportunities at CPHI India 2026
Where can I discuss DC granules at CPHI India 2026?
Visit Rraynex Pharmaceuticals at Stall Number 1A50 to discuss the listed pharmaceutical granule and direct-compression references. Bring the intended tablet process and target composition.
Which MUPS products can I discuss?
The listed portfolio includes Omeprazole MUPS, Esomeprazole MUPS, Dexlansoprazole MUPS and profile-listed Dexlansoprazole DDR MUPS. Confirm the exact specification and current availability for the project.
Can formulation companies discuss EC, SR and IR pellets?
Yes. Share the selected molecule, release objective, loading basis and intended dosage form so the team can identify the relevant material and evidence.
What technical documentation should I request?
List the specification, batch analysis, stability, safety and regulatory-support documents your team needs. Availability and applicability depend on the exact product, site and market.
Meet Rraynex at CPHI India 2026 to explore pharmaceutical manufacturing, global B2B supply, multivitamin pellets and nutraceutical premixes at Stall Number 1A50.